DiaGenic provides update on key clinical programs
Monday, 29 July 2013
DiaGenic the Norwegian medical company announces that the validation study for MCItect®, a blood based diagnostic test for Alzheimer’s disease in the pre-dementia stage, has failed to reach the study goals.
Consequently, DiaGenic will not pursue CE-marking or U.S. trials with the current version of MCItect®.
The clinical study for the company’s other key product AMYtect™ has
successfully recruited 100 patients and will enter the analysis phase
in August.
In a press release, the company writes that in the development of
MCItect®, DiaGenic reported results on July 17th 2012 from a 60-patient
study demonstrating a total prediction accuracy of 74 percent in
detecting patients converting from mild cognitive impairment to
Alzheimer’s disease dementia.
Utilizing an improved assay methodology and instrumentation, a separate
non-overlapping subset of genes increased the prediction accuracy to
81percent.
Read more from DiaGenic.
by Scancomark.com Team
Granscole Studios Web design Pro | Web analysis | Operations Management Consult | Marketing Consult |
Support and Contact Support | Corrections | Contact Us
Connect with Scandinavian Companies and Market